Watson Pharmaceuticals, Inc.
27Patents
9Active
27Granted
39Portfolio score
Filing activity: Feb 12, 1998 → Oct 22, 2013 · 5 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6210699A | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity | Human Necessities | 112 | Expired |
| US6583129B1 | Administration of non-oral androgenic steroids to women | Human Necessities | 79 | Expired |
| US6544553B1 | Dosage forms and methods for oral delivery of progesterone | Human Necessities | 75 | Expired |
| US6866865B2 | Dosage forms and methods for oral delivery of progesterone | Human Necessities | 65 | Expired |
| US6365178B1 | Method of making pressure sensitive adhesive matrix patches for transdermal drug delivery using hydrophilic salts of drugs and hydrophobic pressure sensitive adhesive dispersions | Human Necessities | 56 | Expired |
| US6585963B1 | Nail compositions and methods of administering same | Human Necessities | 47 | Expired |
| US6153223A | Stabilized pharmaceutical compositions | Human Necessities | 29 | Expired |
| USD439654S | Tablet | General | 24 | Expired |
| US6180133A | Antioxidant composition for topical/transdermal prevention and treatment of wrinkles | Human Necessities | 23 | Expired |
| US7186706B2 | Administration of non-oral androgenic steroids to women | Human Necessities | 22 | Expired |
| US6743441B2 | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy | Human Necessities | 22 | Expired |
| US6727401B1 | Pressure sensitive adhesive matrix patch for the treatment of onychomycosis | Human Necessities | 19 | Expired |
| USD440650S | Tablet | General | 15 | Expired |
| US6730318B2 | Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties | Human Necessities | 6 | Expired |
| US7179483B2 | Compositions and methods for transdermal oxybutynin therapy | Human Necessities | 5 | Expired |
| US7785627B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | Human Necessities | 4 | Active |
| US7959946B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | Human Necessities | 4 | Active |
| US9198858B2 | Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations | Human Necessities | 3 | Active |
| US6693083B2 | Conjugates targeted to the interleukin-2 receptor | Emerging Cross-Sectional Technologies | 3 | Expired |
| US7338667B2 | Pharmaceutical formulation | Human Necessities | 3 | Expired |
| US6630166B1 | Compositions for conjugated estrogens and associated methods | Human Necessities | 1 | Expired |
| US8470368B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | Human Necessities | 1 | Active |
| US8084058B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | Human Necessities | 1 | Active |
| US8309125B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | Human Necessities | 1 | Active |
| US8597683B2 | Modified release tranexamic acid formulation | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.